ReShape Lifesciences raises $2.5M via registered direct offering and private placement at $3.07/unit

Vyome Holdings, Inc

Entered into securities purchase agreement with institutional investor for 800,695 shares/pre-funded warrants at $3.07/unit, raising ~$2.5M gross.
Concurrent private placement of warrants to purchase 800,695 shares at $3.07, exercisable immediately, expire in 5.5 years.
Amended existing warrants for 164,656 shares from $15.00 to $3.07 exercise price effective upon closing.
Placement agent Maxim Group receives 7% cash fee and 40,035 warrants at $3.38 exercise price.
Offering expected to close on or about April 24, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Vyome Holdings, Inc entered into Securities Purchase Agreement with a certain institutional investor valued at approximately $2.46 million (effective 2023-04-20).

Action: entry
Agreement: equity purchase
Counterparty: a certain institutional investor
Value: approximately $2.46 million
Effective: 2023-04-20

Exact text from the filing

On April 20, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 291,395 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) pre-funded warrants to purchase an aggregate of 509,300 shares of Common Stock (the “Pre-funded Warrants”).

View on SEC.gov

Browse all material agreements →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-050338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.